| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 05/27/1999 | WO1999025359A1 New composition of matter |
| 05/27/1999 | WO1999025357A1 USE OF 9-DEOXY-2', 9-α-METHANO-3- OXA-4,5,6- TRINOR-3, 7-(1',3'-INTERPHENYLENE) -13,14-DIHYDRO- PROSTAGLANDIN F1 TO TREAT PERIPHERAL VASCULAR DISEASE |
| 05/27/1999 | WO1999025354A2 Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters |
| 05/27/1999 | WO1999025349A1 Anaesthetic formulation |
| 05/27/1999 | WO1999025343A1 Granules comprising clavulanate and one or more excipients |
| 05/27/1999 | WO1999025341A1 Use of histamine for elevating blood histamine levels |
| 05/27/1999 | WO1999025338A1 Pharmaceutical composition containing zafirlukast |
| 05/27/1999 | WO1999025337A1 Composition of ingredients for a beverage having a delayed aversion effect |
| 05/27/1999 | WO1999025332A1 Composition with azelaic acid |
| 05/27/1999 | WO1999025326A1 Prolamin-plant polar lipid combination, preparation method and applications |
| 05/27/1999 | WO1999025325A1 Low temperature coatings |
| 05/27/1999 | WO1999025324A1 Administering active substances by using the capsid produced out of the polyoma virus vp1 protein |
| 05/27/1999 | WO1999025323A1 Omeprazole formulation |
| 05/27/1999 | WO1999025322A2 Pharmaceutical compositions having the shape of powders of cross-linked polymers loaded with drugs and related preparation process by supercritical fluids |
| 05/27/1999 | WO1999025321A1 High drug load immediate and modified release oral dosage formulations and processes for their manufacture |
| 05/27/1999 | WO1999025320A1 Targeted liposome gene delivery |
| 05/27/1999 | WO1999025319A1 Production of multivesicular liposomes |
| 05/27/1999 | WO1999017739B1 Aerosol ointment compositions and method of manufacture |
| 05/27/1999 | WO1999012563A3 Mucosal cytotoxic t lymphocyte responses |
| 05/27/1999 | WO1999012529A3 Transdermal therapeutic system comprising a reservoir-type pressure-sensitive adhesive layer and a back layer with uni-directional resilience |
| 05/27/1999 | WO1999009961A3 Drain system containing additives |
| 05/27/1999 | DE19813174A1 Gas-filled microparticles, used for administering biologically active substances |
| 05/27/1999 | DE19750453A1 Preparation of hypocholesterinemic agents |
| 05/27/1999 | DE19750354A1 Covering an inductor molecule with a viral capsid, for more efficient transfection of cells |
| 05/27/1999 | CA2739604A1 Targeted liposome gene delivery |
| 05/27/1999 | CA2310423A1 Pharmaceutical compositions having the shape of powders of cross-linked polymers loaded with drugs and related preparation process by supercritical fluids |
| 05/27/1999 | CA2310255A1 Use of histamine for elevating blood histamine levels |
| 05/27/1999 | CA2310138A1 Prolamin-plant polar lipid combination, preparation method and applications |
| 05/27/1999 | CA2310026A1 Hypocholesteremic preperations containing mixtures of phytostenol(ester)s and conjugated fatty acids, and methods of reducing serum cholesterol levels using the same |
| 05/27/1999 | CA2309548A1 Production of multivesicular liposomes |
| 05/27/1999 | CA2272402A1 Granules comprising clavulanate and one or more excipients |
| 05/26/1999 | EP0917879A2 Procédé amélioré pour la stabilisation des protéines |
| 05/26/1999 | EP0917875A1 Aqueous eye drops containing apafant as principal agent |
| 05/26/1999 | EP0917872A1 A composition for delivering drug by ionotophoresis |
| 05/26/1999 | EP0917869A2 Use of water-in-oil emulsions as thickening agents in cosmetical and pharmaceutical compositions |
| 05/26/1999 | EP0917473A1 Covalent polar lipid conjugates with biologically-active compounds for use in salves |
| 05/26/1999 | EP0917463A2 Tramadol multiple unit formulations |
| 05/26/1999 | EP0917461A1 Device for topical treatment of acne and its method of manufacture |
| 05/26/1999 | EP0917460A1 Cyclosporin formulation |
| 05/26/1999 | EP0917459A1 Tablet dosage form of clavulanic acid and amoxycillin comprising a trehalose excipient |
| 05/26/1999 | EP0917458A1 Lyophilized thioxanthenone antimumor agents |
| 05/26/1999 | EP0917457A1 Biphasic multicomponent pharmaceutical dosage forms containing substances able to modify the partitioning of drugs |
| 05/26/1999 | EP0917428A1 Hybrid matrix implants and explants |
| 05/26/1999 | EP0844909B1 Encapsulated product |
| 05/26/1999 | EP0836506A4 Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen |
| 05/26/1999 | EP0804245B1 Collagen preparation for the controlled release of active substances |
| 05/26/1999 | EP0678034B1 Inducing cytotoxic t lymphocyte responses |
| 05/26/1999 | CN1217733A Polymer powders redispersible in aqueous solution |
| 05/26/1999 | CN1217731A Improved preparation method for biodegradable polymeric microspheres using solvent extraction and preparation method for microspheres for treating local inflammation using same |
| 05/26/1999 | CN1217659A Process for preparing storable preparation from fresh plant and fresh plant preparation |
| 05/26/1999 | CN1217658A Dicloroanilicnophenylacetic acid/gamma-cyclodextrin inclusion compounds |
| 05/26/1999 | CN1217657A Nasal administration of agents for treatment of delayed onset emesis |
| 05/26/1999 | CN1217656A Patch containing isosorbide dinitrate |
| 05/26/1999 | CN1217655A Modified release multiple-units dosage composition |
| 05/26/1999 | CN1217654A Process for production of powdered pulmoney surfactant preparations |
| 05/26/1999 | CN1217212A Vaccine both for hepatitis A and measles and production method therefor |
| 05/26/1999 | CN1217210A Plaster for intensifying vigour of liver and production process therefor |
| 05/26/1999 | CN1217209A Anti-cancer medicine |
| 05/26/1999 | CN1217206A Phytodrug for treatment and management of sickle cell anemia and method of preparing and using same |
| 05/26/1999 | CN1217197A Liniment for treating bony spur |
| 05/26/1999 | CN1217193A Plaster for promoting recovery of psora and production process therefor |
| 05/26/1999 | CN1217187A Anti-parasite oral spray containing evericin and ivermectin for sheep |
| 05/26/1999 | CN1217184A Controlled-release preparation of Tekening (medicine) |
| 05/25/1999 | US5906991 Releasing and absorption, suspension and heating |
| 05/25/1999 | US5906922 Delivery of nucleic acids |
| 05/25/1999 | US5906833 Chronological food bar |
| 05/25/1999 | US5906832 Time release agents for epileptic drugs into intestines |
| 05/25/1999 | US5906831 Consists of monocaproin, a polar liquid selected from ethylene glycol, propylene glycol, ethanol, glycerol and water, a biologically active material such as protein, petide, nucleic acid, vitamine or vaccine; sustained release of a drug |
| 05/25/1999 | US5906830 Supersaturated transdermal drug delivery systems, and methods for manufacturing the same |
| 05/25/1999 | US5906829 Poultice comprising a titanium-based material |
| 05/25/1999 | US5906826 Adminstering a biocompabilbe solid implant having the antigen releasably contained therein during a period when maternal antiboides are circulating in a mammal and are effective to stimulate active immunity |
| 05/25/1999 | US5906825 Polymers containing antimicrobial agents and methods for making and using same |
| 05/25/1999 | US5906822 Amphiphilic, hydrophilic or lipophilic polyetherurethane copolymers for moisturizing skin and hair |
| 05/25/1999 | US5906817 Biocompatible implant for the expression and in vivo secretion of a therapeutic substance |
| 05/25/1999 | US5906814 Topical film-forming compositions |
| 05/25/1999 | CA2151742C Compositions for oral delivery of active agents |
| 05/25/1999 | CA2138977C Cosmetic containing phospholipids and fluorocarbon compounds |
| 05/25/1999 | CA2135062C Pharmaceutical and other dosage forms |
| 05/25/1999 | CA2126611C Opiod formulations having extended controlled release |
| 05/25/1999 | CA2085875C Starch encapsulation of biologically active agents by a continuous process |
| 05/25/1999 | CA2073431C Interdigitation-fusion liposomes and gels |
| 05/20/1999 | WO1999024582A1 Novel reovirus-derived proteins, nucleic acids encoding same, and uses therefor |
| 05/20/1999 | WO1999024490A1 Strictly alternating poly(alkylene oxide ether) copolymers |
| 05/20/1999 | WO1999024391A1 Radio-opaque polymer biomaterials |
| 05/20/1999 | WO1999024213A1 Laser beam cutting method for cutting laminates for applying to the skin |
| 05/20/1999 | WO1999024159A1 Encapsulate of active material in alginate matrix |
| 05/20/1999 | WO1999024107A1 Biodegradable, anionic polymers derived from the amino acid l-tyrosine |
| 05/20/1999 | WO1999024073A1 Pharmaceutical compositions containing cyclodextrins and taxoids |
| 05/20/1999 | WO1999024072A1 Release-sustaining agent for drugs and sustained-release pharmaceutical composition |
| 05/20/1999 | WO1999024071A1 Method for decreasing self-association of polypeptides |
| 05/20/1999 | WO1999024070A2 Ester derivatives of hyaluronic acid with viscoelastic properties and their use in the biomedical and healthcare field |
| 05/20/1999 | WO1999024063A1 Compositions providing for increased igf-i solubility |
| 05/20/1999 | WO1999024062A1 Novel igf-i composition and its use |
| 05/20/1999 | WO1999024061A1 Method for producing igf-1 sustained-release formulations |
| 05/20/1999 | WO1999024043A1 Viscous compositions containing carbon dioxide |
| 05/20/1999 | WO1999024042A2 Stable antiandrogenic gel composition |
| 05/20/1999 | WO1999024041A1 Penetration enhancing and irritation reducing systems |
| 05/20/1999 | WO1999024036A1 Skin penetration enhancing components |
| 05/20/1999 | WO1999024032A1 Transdermal delivery of 3,4-diarylchromans |
| 05/20/1999 | WO1999024024A2 Treatment of t-helper cell type 2 mediated immune diseases with retinoid antagonists |